The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature

World J Urol. 2020 Mar;38(3):657-662. doi: 10.1007/s00345-019-02744-4. Epub 2019 Apr 2.

Abstract

Purpose: To systematically and comprehensively review and summarize the most recent literature assessing the value of the new grading system introduced by the International Society of Urological Pathology (ISUP) in 2014 and accepted by the World Health Organization (WHO) in 2016.

Methods: A systematic literature search in the PubMed database was performed up to November 2018. Overall, 15 studies in the period from 2016 to 2018 evaluating the new grading system have been selected for evidence synthesis.

Results: The main goals of the new ISUP 2014/WHO 2016 grading system were to establish (I) a more accurate and simplified grade stratification, (II) less overtreatment of indolent prostate cancer as well as (III) an improved patient communication. The majority of the studies chose biochemical recurrence as an endpoint for evaluation and statistically assigns the new ISUP 2014/WHO 2016 grading system a higher prognostic accuracy than the former Gleason grading. However, in only a subset of studies it was clearly evident that the historical samples were not only re-grouped according to the new grade groups but also re-graded according to the new histomorphological 2014 ISUP criteria.

Conclusions: The vast majority of the studies support an improved prognostic accuracy of the ISUP 2014/WHO 2016 grade groups and endorse its worldwide application.

Keywords: Grade group; International Society of Urological Pathology (ISUP); Prognosis; Prostate cancer; World Health Organization (WHO).

Publication types

  • Systematic Review

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / pathology*
  • Humans
  • Kallikreins / blood
  • Male
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / blood
  • Neoplasm Recurrence, Local / epidemiology*
  • Practice Guidelines as Topic*
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / pathology*
  • World Health Organization

Substances

  • KLK3 protein, human
  • Kallikreins
  • Prostate-Specific Antigen